Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer

In this discussion panel with Pharmacy Times, Meredith Pelster, MD, MSCI; Ben Zeskind, PhD; and Igor Matushansky, MD, PhD, discuss Immuneering’s investigational MEK inhibitor atebimetinib and its potential to reshape first-line treatment for pancreatic cancer. The panel reviews phase 2 data showing a 64% overall survival rate at 12 months, representing a meaningful improvement over historical benchmarks in a disease with limited therapeutic progress.